|
1.
|
|
15 p, 3.7 MB |
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
/
Botta, Cirino (Clínica Universidad de Navarra) ;
Perez, Cristina (Clínica Universidad de Navarra) ;
Larrayoz, Marta (Clínica Universidad de Navarra) ;
Puig, Noemí (Hospital Universitario de Salamanca) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre) ;
Termini, Rosalinda (Clínica Universidad de Navarra) ;
Goicoechea, Ibai (Clínica Universidad de Navarra) ;
Rodriguez, Sara (Clínica Universidad de Navarra) ;
Zabaleta, Aintzane (Clínica Universidad de Navarra) ;
Lopez, Aitziber (Clínica Universidad de Navarra) ;
Sarvide, Sarai (Clínica Universidad de Navarra) ;
Blanco, Laura (Clínica Universidad de Navarra) ;
Papetti, Daniele Marco (Department of Informatics. University of Milano-Bicocca) ;
Nobile, M.S. (Biostatistics and Bioimaging Centre-B4) ;
Besozzi, Daniela (Biostatistics and Bioimaging Centre-B4) ;
Gentile, Massimo (Department of Oncohematology. "Annunziata" Hospital) ;
Correale, Pierpaolo (Great Metropolitan Hospital "Riuniti" of Reggio Calabria) ;
Siragusa, Sergio (Department of Health Promotion. University of Palermo) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Garcia, Maria Esther (Hospital Universitario de Cabueñes (Gijón)) ;
Sureda, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
de Arriba, Felipe (Instituto Murciano de Investigación Biosanitaria) ;
Ríos-Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Moraleda, José María (Instituto Murciano de Investigación Biosanitaria) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Hernández, Miguel T. (Hospital Universitario de Canarias (Illes Canàries)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Illes Balears)) ;
Palomera, Luís (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Pérez-Montaña, Albert (Hospital Universitari Son Espases (Illes Balears)) ;
Goldschmidt, Hartmut (Department of Internal Medicine V. University of Heidelberg) ;
Avet-Loiseau, Hervé (IUC-T Oncopole) ;
Roccaro, Aldo (Department of Hematology. ASST Spedali Civili di Brescia) ;
Orfao, Alberto (Universidad de Salamanca. Departament de Medicina) ;
Martinez-Lopez, Joaquín (Hospital Universitario 12 de Octubre) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Mateos, M. V (Hospital Universitario de SalamancaBiomedica de Salamanca (IBSAL). Centro de Investigación del Cancer (IBMCC-USAL. CSIC)) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Martinez Climent, Juan-José (Clínica Universidad de Navarra) ;
Paiva, Bruno (Clínica Universidad de Navarra)
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). [...]
2023 -  10.1038/s41467-023-41562-6
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 5825
|
|
|
2.
|
|
13 p, 471.4 KB |
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial
/
Dimopoulos, Meletios (National and Kapodistrian University of Athens) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nahi, Hareth (Department of Medicine. Karolinska University) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Bahlis, Nizar J. (University of Calgary) ;
Usmani, S. Z (Memorial Sloan Kettering Cancer Center) ;
Rabin, Neil (Department of Haematology. University College London Hospitals NHS Trust) ;
Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas) ;
Suzuki, Kenshi (Department of Hematology. Japanese Red Cross Medical Center) ;
Plesner, Torben (University of Southern Denmark) ;
Yoon, Sung Soo (Department of Internal Medicine. Seoul National University) ;
Ben Yehuda, Dina (Hematology Department. Hebrew University) ;
Richardson, Paul G. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Goldschmidt, Hartmut (Heidelberg University Hospital (Alemanya)) ;
Reece, Donna (Department of Medical Oncology and Hematology. Princess Margaret Cancer Centre) ;
Ahmadi, Tahamtan (Genmab US (Estats Units d'Amèrica)) ;
Qin, Xiang (Janssen Research & Development (Xina)) ;
Garvin Mayo, Wendy (Janssen Research & Development (Estats Units d'Amèrica)) ;
Gai, Xue (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carey, Jodi (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carson, Robin (Janssen Research & Development (Estats Units d'Amèrica)) ;
Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
PURPOSEWith the initial analysis of POLLUX at a median follow-up of 13. 5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2023 - 10.1200/JCO.22.00940
Journal of Clinical Oncology, Vol. 41 Núm. 8 (october 2023) , p. 1590-1599
|
|
|
3.
|
|
4 p, 756.5 KB |
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS
/
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Haenel, M. (Klinikum Chemnitz, Germany) ;
Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ;
Ailawadhi, Sikander (Mayo Clinic Florida, USA) ;
Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ;
de la Rubia Comos, Javier (Catholic University of Valencia) ;
Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ;
Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ;
Terebelo, Howard (Providence Cancer Center, Southfield, USA) ;
Yang, Shiyi (Janssen Research & Development. LLC, USA) ;
Wang, Jianping (Janssen Research & Development. LLC, USA) ;
Nnane, Ivo (Janssen Research & Development. LLC, USA) ;
Qi, Ming (Janssen Research & Development. LLC, USA) ;
Kosh, Michele (Janssen Research & Development. LLC, USA) ;
Delioukina, Maria (Janssen Research & Development. LLC, USA) ;
Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)
|
|
|
4.
|
|
18 p, 2.5 MB |
The EHA Research Roadmap : Malignant Lymphoid Diseases
/
Dreyling, Martin (LMU Hospital (Alemanya)) ;
André, Marc (Université Catholique de Louvain (bèlgica)) ;
Gökbuget, Nicola (Goethe University (Alemanya)) ;
Tilly, Hervé (Centre Henri Becquerel and Université de Rouen (França)) ;
Jerkeman, Mats (Skåne University and Lund University (Suècia)) ;
Gribben, John (Queen Mary University of London (Regne Unit)) ;
Ferreri, Andrés (IRCCS San Raffaele Scientific Institute (Itàlia)) ;
Morel, Pierre (CHU Amiens Picardie (França)) ;
Stilgenbauer, Stephan (Universität Ulm (Alemanya)) ;
Fox, Christopher (University of Nottingham (Regne Unit)) ;
Maria Ribera, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zweegman, Sonja (Amsterdam UMC (Països Baixos)) ;
Aurer, Igor (University of Zagreb (Zagreb)) ;
Bödör, Csaba (Semmelweis University (Hongria)) ;
Burkhardt, Birgit (Pädiatrische Hämatologie und Onkologie (Alemanya)) ;
Buske, Christian (University Hospital of Ulm (Alemanya)) ;
Dollores Caballero, Maria (El Instituto de Investigación Biomédica de Salamanca (Salamanca, Espanya)) ;
Campo, Elias (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Chapuy, Bjoern (Berlin Institute of Health (Alemanya)) ;
Davies, Andrew (University of Southampton (Regne Unit)) ;
de Leval, Laurence (Lausanne University Switzerland (Suïssa)) ;
Doorduijn, Jeanette (University Medical Center Rotterdam the Netherlands (Països Baixos)) ;
Federico, Massimo (GVM Care & Research (Itàlia)) ;
Gaulard, Philippe (Hôpital Henri Mondor (França)) ;
Gay, Francesca (AOU Città Della Salute e Della Scienza (Itàlia)) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele (Itàlia)) ;
Grønbæk, Kirsten (University of Copenhagen (Dinamarca)) ;
Goldschmidt, Hartmut (University Hospital Heidelberg (Alemanya)) ;
Kersten, Marie-Jose (Cancer Center Amsterdam and LYMMCARE the Netherlands (Països Baixos)) ;
Kiesewetter, Barbara (Medical University of Vienna (Àustria)) ;
Landman-Parker, Judith (Sorbonne Université APHP/hôpital A Trousseau (França)) ;
Le Gouill, Steven (Clinique du Centre Hospitalier Universitaire (CHU) de Nantes (França)) ;
Lenz, Georg (Medical University Hospital Münster (Alemanya)) ;
Leppä, Sirpa (Helsinki University Hospital Comprehensive Cancer Centre Finland (Finlandia)) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Macintyre, Elizabeth (Assistance Publique-Hôpitaux de Paris (França)) ;
Mantega, Maria Victoria Mateos (Universidad de Salamanca (Salamanca, Espanya)) ;
Moreau, Philippe (University Hospital Hotel-Dieu (França)) ;
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Nadel, Bertrand (Aix Marseille Univ (França)) ;
Okosun, Jessica (Queen Mary University of London (Regne Unit)) ;
Owen, Roger (St James's Institute of Oncology (Regne Unit)) ;
Pospisilova, Sarka (University Hospital Brno (Txèquia)) ;
Pott, Christiane (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Robak, Tadeusz (Medical University of Lodz (Polònia)) ;
Spina, Michelle (National Cancer Institute (Itàlia)) ;
Stamatopoulos, Kostas (Centre for Research and Technology Hellas Greece (Grècia)) ;
Stary, Jan (Charles University Prague University Hospital Czech Republic (Txèquia)) ;
Tarte, Karin (Immunology and Cell Therapy Lab at Rennes University Hospital (França)) ;
Tedeschi, Allessandra (Niguarda Hospital Milano (Itàlia)) ;
Thieblemont, Catherine (Assistance Publique-Hôpitaux de Paris (França)) ;
Trappe, Ralf Ulrich (DIAKO Hospital Bremen (Alemanya)) ;
Trümper, Lorenz H. (University Medicine Goettingen (Alemanya)) ;
Salles, Gilles (Weill Cornell Medicine (Estats Units)) ;
Universitat Autònoma de Barcelona
2022 - 10.1097/HS9.0000000000000726
HemaSphere, Vol. 6 (may 2022)
|
|
|
5.
|
|
10 p, 1.8 MB |
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma : Updated Overall Survival, Safety, and Subgroups
/
Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas M.D. Anderson Cancer Center) ;
Moreau, Philippe (Department of Hematology. University Hospital Hotel-Dieu) ;
Niesvizky, Ruben (Department of Medical Oncology. Myeloma Center. New York Presbyterian Hospital-Weill Cornell Medical Center) ;
Ludwig, Heinz (Wilhelminen Cancer Research Institute (Viena, Àustria)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Chng, Wee Joo (Department of Hematology Oncology. National University of Singapore) ;
Goldschmidt, Hartmut (Department of Hematology Oncology. Heidelberg University Clinic and the National Center of Tumor Diseases) ;
Yang, Zhao (Department of Biostatistics. Amgen. Inc) ;
Kimball, Amy S. (Department of Clinical Research. Amgen. Inc) ;
Dimopoulos, Meletios (Department of Clinical Therapeutics. University Athens School of Medicine) ;
Universitat Autònoma de Barcelona
Introduction: The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2019 - 10.1016/j.clml.2019.04.018
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 8 (august 2019) , p. 522-530.e1
|
|
|
6.
|
|
11 p, 1.4 MB |
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
/
Weisel, Katja (Department of Hematology. Oncology. Immunology. Rheumatology. and Pulmonology. Medical Clinic II) ;
Majer, Istvan (Amgen Europe GmbH) ;
DeCosta, Lucy (Amgen Ltd) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Goldschmidt, Hartmut (Internal Medicine V and National Center of Tumor Diseases. University Clinic Heidelberg) ;
Ludwig, Heiz (Wilhelminen Cancer Research Institute (Viena, Àustria)) ;
Campioni, Marco (Amgen Europe GmbH) ;
Szabo, Zsolt (Amgen Europe GmbH) ;
Dimopoulos, Meletios (School of Medicine. National and Kapodistrian University of Athens. Alexandra Hospital) ;
Universitat Autònoma de Barcelona
In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. [...]
2020 - 10.1080/10428194.2019.1648806
Leukemia and Lymphoma, Vol. 61 Núm. 1 (february 2020) , p. 37-46
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
